15.8  0.08 (0.51%)		04-29 14:31
Open: 15.73 High: 15.995 Volume: 18,023		Pre. Close: 15.72 Low: 15.5367 Market Cap: 397(M)

Short term
Mid term
Targets	6-month :	18.74	1-year :	21.89
Resists	First :	16.04	Second :	18.74
Pivot price	15.52
Supports	First :	14.72	Second :	13.89
MAs	MA(5) :	15.86	MA(20) :	0
	MA(100) :	0	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	0	D(3) :	0
RSI	RSI(14): 55.2
52-week	High :	16.04	Low :	14.31

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CTNM ] has closed below upper band by 33.0%. Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	16.03 - 16.11	16.11 - 16.17
Low:	15.36 - 15.46	15.46 - 15.53
Close:	15.57 - 15.73	15.73 - 15.83

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Fri, 05 Apr 2024
Contineum prices $110M IPO to advance LPA1R antagonists - BioWorld Online

Fri, 05 Apr 2024
Gunderson, Sidley Steer Biotech's Scaled-Down $110M IPO - Law360

Wed, 03 Apr 2024
Contineum Therapeutics Finalizes $150 Million IPO Terms (NASDAQ:CTNM) - Seeking Alpha

Mon, 29 Apr 2024

Mon, 29 Apr 2024

Mon, 29 Apr 2024

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	23 (M)
Shares Float	2 (M)
Held by Insiders	8.6 (%)
Held by Institutions	47.2 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	45.4 %
Operating Margin	32.1 %
Return on Assets (ttm)	11.1 %
Return on Equity (ttm)	27.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	2.13
EBITDA (p.s.)	0.69
Qtrly Earnings Growth	0 %
Operating Cash Flow	19 (M)
Levered Free Cash Flow	13 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	7.39
Price to Cash Flow	19.1

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.